Alto Is Aiming to Redefine Psychiatry

Modern medicine hasn’t made big strides in managing psychiatric disorders, a growing challenge with global implications. “The treatment of psychiatric disorders hasn’t changed from what it was like 30 years ago, medications are given by trial and error and we don’t really know what’s going to work,” Amit Etkin, CEO of Alto Neuroscience, tells Bloomberg Intelligence in this episode of the Vanguards of Health Care podcast. BI senior health-care associate Jean Rivera Irizarry joins Dr. Etkin for an in-depth interview about Alto, how it was formed, its drug-selection process and how the company aims to redefine the way we treat such disorders.See omnystudio.com/listener for privacy information.